Navigation Links
Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection

and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Safety Data: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were asthenic conditions (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients reported at least one episode of grade 4 toxicity; the most common grade 4 toxicities were thrombocytopenia (5%) and neutropenia (3%). Fifty percent of patients reported serious adverse events. The most commonly reported serious adverse events were pneumonia (7%), pyrexia (6%), diarrhea (5%), vomiting (4%), and nausea, dehydration, dyspnea and thrombocytopenia (each 3%).

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of nine innovative product candidates. Millennium's website is




Page: 1 2 3 4 5 6

Related medicine technology :

1. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
2. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
3. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
11. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
Post Your Comments:
(Date:9/29/2014)... SAN DIEGO , 29. ... Ltd. (nachstehend Daiichi Sankyo) (TSE: 4568) und ... gaben heute gemeinsam eine definitive Fusionsvereinbarung bekannt, ... von Ambit Biosciences für 15 US-Dollar je ... anschließenden Zusammenschluss mit einem Tochterunternehmen von Daiichi ...
(Date:9/29/2014)... IRVING, Texas , Sept. 29, 2014 /PRNewswire/ ... 340B Drug Pricing Program, has announced that it ... Services Administration (HRSA) to continue serving in its ... 2019. Apexus, which has held this position for ... with more than 25,000 safety-net provider locations, drug ...
(Date:9/29/2014)... SEATTLE , Sept. 29, 2014 ... leverages Next Generation Sequencing to profile the adaptive ... a Scientific Advisory Board to provide strategic and ... diagnostic suite of assays in the diagnosis and ... initial focus of the SAB will be to ...
Breaking Medicine Technology:Daiichi Sankyo wird Ambit Biosciences übernehmen 2Daiichi Sankyo wird Ambit Biosciences übernehmen 3Daiichi Sankyo wird Ambit Biosciences übernehmen 4Daiichi Sankyo wird Ambit Biosciences übernehmen 5Daiichi Sankyo wird Ambit Biosciences übernehmen 6Daiichi Sankyo wird Ambit Biosciences übernehmen 7Daiichi Sankyo wird Ambit Biosciences übernehmen 8Apexus Wins HRSA Contract to Remain Prime Vendor of 340B Program 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3
... RESEARCH TRIANGLE PARK, N.C., Oct. 16 Liquidia,Technologies ... founder,and University of North Carolina-Chapel Hill professor, Joseph ... DeSimone will discuss drug delivery,applications of the PRINT(TM) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20060614/CLW002LOGO ), -- ...
... went to see Dr. Peter Hersey, a medical oncologist ... was told he only had three,to six months to ... one,of the most difficult to treat forms of cancer. ... previously treated,area of his face and nothing was helping ...
Cached Medicine Technology:Targeted Nanoparticles Offer Promise in the Battle Against Cancer 2Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years 2
(Date:9/30/2014)... 2014 From October 12-15, MMS, ... the 2014 SHSMD Connections Annual Conference in San Diego, ... & Market Development (SHSMD) is proud to host the ... and communications, and strategic planning professionals in San Diego ... , The conference is a four-day event designed ...
(Date:9/30/2014)... IN (PRWEB) September 30, 2014 ... Ron Receveur encourages all persons who have received dental ... in a recent blog post. , The post, which ... with dental implants that if they don’t brush and ... same way people lose their natural teeth: the bone ...
(Date:9/30/2014)... “Biology and botany are having an ... it’s about naming rights.” , In Homeostasis: ... the Bryan William Brickner Blog, the focus is ... Health (PubMed). The post highlights five cannabinoid system ... aging with THC, the wake-inducing effects of CBD, ...
(Date:9/30/2014)... September 30, 2014 Named a ... East Longmeadow facility has officially announced that they ... that combines advanced medical technology with supportive, ... one of the only non-hospital options available in ... The primary focus of this Ventilator Program ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 American Medical ... a collaborative agreement to raise awareness about Alzheimer’s disease ... IDs for people with these brain disorders. , American ... generated by AFA to the foundation to support its ... their families. The ID bracelets and necklaces can be ...
Breaking Medicine News(10 mins):Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 2Health News:All on Four Dental Implants Dentist Writes Blog on Preventing Gum Disease 3Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 3Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 2Health News:American Medical ID and Alzheimer’s Foundation of America Team up to Increase Awareness about Alzheimer’s Disease and Related Dementias 3
... study by a Swedish researcher on the effects of the ... likely to occur when they have their period. The// researcher ... fluctuations causing the levels of relaxin (a hormone which relaxes ... studied for the research and it was seen that women ...
... from fatty foods that we eat. A certain amount// of cholesterol ... keep the body healthy but a high level can lead to ... a build up of small fatty lumps developing on the inside ... are at greater risk if we smoke, have high blood pressure ...
... a press release the Ministry of Health has indicated the current ... on Dengue// the Ministry has confirmed reports of 9453 cases ... upto 12 .30 hrs. ,In Delhi and NCR - ... of 2872 cases and 59 deaths have been reported from Delhi, ...
... access to a high-profile detainee at Guantanamo Bay, Cuba, ... secrets" whose revelation could "cause extremely grave damage", the ... at secret CIA prisons must not be allowed to ... even to their lawyers, the Post reported.,A lawyer at ...
... medical problems and surgeries in space before astronauts start moving ... a person develops a problem say, in Mars? He or ... time simply because it takes over three years to reach ... little difference in the dose of general anesthesia needed to ...
... industry which has been simmering in the trans-fat controversy for ... their sticky ally- the hydrogenated// vegetable oils! This is perhaps ... & Spencer, Asda, Sainsbury’s and Tesco have already communicated their ... British Medical Journal has urged the Government to bring in ...
Cached Medicine News:Health News:Researchers explore medicine in space 2Health News:Researchers explore medicine in space 3
Full Handle Laseredge Crescent Blade Knife, angled double bevel. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 45 blade. Blade tip dimension: 8.9 mm x 1.9 mm x 1.9 mm....
Full Handle Laseredge Stab Blade Knife, 15 blade. Blade tip dimension: 3 mm x 1.0 mm x 3.0 mm....
Medicine Products: